Plain-English translation of NCT07221851 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new form of growth hormone called lonapegsomatropin that is given once per week, compared to the standard daily growth hormone injection (somatropin). Researchers want to see if the weekly injection works just as well as daily injections for children and teenagers with short stature caused by conditions like Turner syndrome, SHOX gene mutations, being small for gestational age, or idiopathic short stature. The study will follow participants for up to 2 years.
Current growth hormone treatment requires daily injections, which can be difficult for families to manage long-term. This trial exists to see whether a once-weekly version of the medication could be equally effective while being more convenient and easier to stick with over time.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new once-weekly injection for the full 2 years, or the standard daily injection for the first year followed by the weekly injection for the second year. You will give yourself or receive subcutaneous (under-the-skin) injections on a regular schedule and attend clinic visits to be measured, have blood tests, and discuss how treatment is going. The trial takes place over 2 years at centers in the United States, France, Germany, Italy, Romania, Spain, and South Korea.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States